Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
Juan MoroteHayley PyeMiriam CampistolAnna CelmaLucas RegisMaria SemideyInes de TorresRichard MastJacques PlanasAnna SantamariaEnrique TrillaAlcibiade AthanasiouSaurabh SinghSusan HeaveyUrszula Stopka-FarooquiAlex FreemanAiman HaiderRalph SchiessHayley C WhitakerShonit PunwaniHashim Uddin AhmedMark EmbertonPublished in: BJU international (2023)
When combined with mpMRI and prostate volume, Proclarix reliably predicted csPCa and ruled out men with no or indolent cancer. A large reduction of two thirds of unneeded biopsies was achieved. Proclarix can further be used with high confidence to reliably detect csPCa in men with an indeterminate PI-RADS 3 mpMRI. Despite these encouraging results, further validation is needed.